CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

The Chernin Group (TCG)

Marco DeMeireles, Partner

Hidden Opportunities In Digital Health

Marco DeMeireles

Marco DeMeireles

Healthcare in the U.S. is changing. A confluence of factors has made today the perfect time for health & wellness to be revolutionized by technology: growing healthcare costs, consumer dissatisfaction, provider shortages, and, thanks to the pandemic, the acceleration of telehealth and easing regulations. While not much of this is new, consumers now have higher expectations for healthcare services following digitization across nearly every other industry; a trend that’s been furthered by employers who have increasingly pushed the cost burden onto consumers.


In recent years the majority of private capital has focused on generalist platforms; however, there remains a number of specialties that require more targeted solutions and justify increased focus by investors and entrepreneurs alike.


Maternity Care In the US today, over $100Bn is spent annually on prenatal care, labor/delivery, and postpartum. Yet today, the US has the #1 worst rate of maternal mortality in the developed world. Alarmingly, estimates suggest that ~60percent of those deaths are preventable. And over a third of women have at least one avoidable ED visit during their pregnancy - significantly adding to these costs! NICU utilization and avoidable ER visits remain the #1 driver of maternity costs today.


Historically, startups in this market have largely failed to develop a business model aligned with payers that scale in a capital-efficient way. Many of these companies over-rotated to sell employers a “fringe benefit” without a hard ROI or real engagement. Others pursued an all-digital approach (apps with content, education) or all services (private equity style OB-GYN provider roll-ups), both resulting in mixed success.


That is beginning to change with a new set of players, such as Oula. These businesses are showing clear leadership as strong consumer brands that hone in on consumer experience needs with an eye to redesigning the underlying payment model directly with the payers.


 


Psychosomatic Disorders


 The term psychosomatic in this context refers to physical symptoms that are influenced by the mind. Unlike symptoms that stem from a physical cause in the body (e.g., a leg injury or a bacterial infection), effective treatment for these disorders can be hard to find. Two clear examples of this are Eating Disorders and Substance Abuse. Together, over 70M Americans suffer from these conditions, yet the majority of them go undertreated, battling pervasive social stigma. Moreover, both represent chronic-like issues that require long-term, dedicated support (potentially ondemand). The rates of relapse from today’s addiction programs show we have a lot more work to do.


Today, there are a number of interesting approaches emerging for these conditions. Things like vertical communities centered around specific chronic conditions, the proliferation of at-home diagnostics/wearables, and an increasing embrace of digital solutions like Equip and WorkIt. While most of these are still very early, we’re seeing promising results and strong consumer demand for better offerings in each of these end markets.


Looking Forward


 Earlier this month, the WSJ reported that a number of large healthcare systems were intentionally hiding pricing data of common healthcare treatments from consumers. It’s a clear defensive move that shows they are afraid. Like consumer finance, entertainment, and travel, healthcare is on the cusp of a 25-year plus digitization (and consumerization) wave that will redefine the way many services are discovered and procured. In many cases, such as Maternity care, new businesses will better serve consumers pain points surrounding price, experience, and outcomes; and in other cases, such as Anorexia, these new businesses will address trust, community, convenience, and ongoing support, tapping into millions of patients’ pent-up demand. In the years ahead, I aspire to solve the core needs—people, capital, and operations—of emerging growth companies who are using technology to lower the costs, improve outcomes and build better experiences for consumers of healthcare services


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://biotech-startups.lifesciencesreview.com/leadership-perspective/hidden-opportunities-in-digital-health-nwid-420.html